GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
The company uses iPS cells to develop treatments for diseases relating to the kidney
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Subscribe To Our Newsletter & Stay Updated
